Committees

Business Development & Finance Committee

Charter

The Business Development & Finance Committee (BDF) strives to:

  • address the evolving CGT business model and key considerations including clinical development, partnerships, financing, and commercialization.

Projects & Objectives

  • The BDF champions the ISCT Investigators to Investors (I to I) program, which strives to bridge the knowledge gap between investigators and investors within the cell and gene therapy (CGT) sector. 
  • Conducts semi-annual surveys with aim to understand investor perceptions of key opportunities and challenges in the CGT field at the time.
  • Curates topical educational webinars, white papers and roadmaps to support decision-making in cell therapy manufacturing for both the investor and investigator profiles 

Ideal Member Profile

  • Business development executives (e.g., CEOs, SVPs/VPs, etc.)
  • Cell and Gene Therapy investors & analysts, by invitation

Recent Publications

Cell and gene therapy: a snapshot of investor perspectives (Cytotherapy. 2021 May; 23(3):256-260)
A roadmap for cost-of-goods planning to guide economic production of cell therapy products (Cytotherapy. 2017 Dec;19(12):1383-1391)

The Committee

Headshot of Sven Kili

Co-Chair

Sven Kili, MBChB, MRCS (Eng)

Antion Biosciences
United Kingdom

Headshot of Patrick Rivers

Co-Chair

Patrick Rivers, MBA

Aquilo Capital
United States

2022 Members

Sasha Aleksic
FUJIFILM
United States

Kensuke Amemiya
Hitachi
Japan

Attilio Bondanaza
AstraZeneca
Sweden

Ludwig Camusot
Cell Matters
France

Dan Castro
Avectas
United States

Greg Crescenzi
Kytopen
United States

Frederic Faiz
G Con
Europe

Suzanne Farid, PhD

University College London
England

Miguel Forte
Bone Therapeutics
Belgium

Joseph Garrity
Lonza
United States

Asthika Goonewardene
Truist Securities
United States

Richard Harrison
CGT Catapult
United Kingdom

Brian Hawkins, PhD
Pluristyx
United States

Thomas Heathman

Ori Biotech
United Kindgom

Troels Jordansen

Glycostem
Netherlands

Maximiliano Kunze Küllmer, MEng
Cells for Cells
Chile
ESP Leadership Development Programme

Jeff Liter
Luminary Therapeutics
United States

Caroline Rand

Cytiva 
United States

Tim Vickers

G-CON Manufacturing
United States

Isaac Haq 
Archimed 
United States

Michael May, PhD
CCRM
Canada

Bill Milligan 
AventaCell
Canada/ Taiwan

Jennifer Moody, PhD
Danaher Corporation
Canada

Mario Morken
Berkeley Lights
United States

Jack Horgan
MaxCyte
United States 

Joseph Oved 
MSK
United States

Jean-Sebastian Parisse
Aseptic Technologies
Belgium

Caytlin Perlin

cGMPnow
United States

Karolis Rosickas

Regeneus
Australia

Christian Rouldan

Cellares
United States

Mark Sawicki

Cryoport
United States

Mathias Svahn

NextCell Pharma
Germany

David Smith, PhD

Akron Biotech
United States

Stefanos  Theoharis

Bone Therapeutics
United States

Steven Thompson

BioLife
United States

Phil Vanek, PhD
Gamma Biosciences
United States 

Jonathan Yeh

SaiSei Ventures
Canada

Matt Knight

Discovery Life Sciences 
United States

Joe Valdez

Berkley Lights  
United States